Akeso Inc - ESG Rating & Company Profile powered by AI
The analysis of Akeso Inc was assembled by All Street Sevva using leading Cognitive Robots. The assessment of Akeso Inc uses data from across the internet and also from available documents by Akeso Inc. The Disclosure score covers 17 United Nations SDGs including: 'No Poverty', 'Responsible Production & Consumption' and 'Life on Land'.
Akeso Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 0.0, social score of 3.4 and governance score of 4.0.
2.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1481 | Tissue Regenix Group PLC | 2.6 | Medium |
1481 | Twist Bioscience Corp | 2.6 | Medium |
1499 | Akeso Inc | 2.5 | Medium |
1499 | Allergan plc | 2.5 | Medium |
1499 | Joinn Laboratories China Co Ltd | 2.5 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Akeso Inc have an accelerator or VC vehicle to help deliver innovation?
Does Akeso Inc disclose current and historical energy intensity?
Does Akeso Inc report the average age of the workforce?
Does Akeso Inc reference operational or capital allocation in relation to climate change?
Does Akeso Inc disclose its ethnicity pay gap?
Does Akeso Inc disclose cybersecurity risks?
Does Akeso Inc offer flexible work?
Does Akeso Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Akeso Inc disclose the number of employees in R&D functions?
Does Akeso Inc conduct supply chain audits?
Does Akeso Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Akeso Inc conduct 360 degree staff reviews?
Does Akeso Inc disclose the individual responsible for D&I?
Does Akeso Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Akeso Inc disclose current and / or historical scope 2 emissions?
Does Akeso Inc disclose water use targets?
Does Akeso Inc have careers partnerships with academic institutions?
Did Akeso Inc have a product recall in the last two years?
Does Akeso Inc disclose incidents of discrimination?
Does Akeso Inc allow for Work Councils/Collective Agreements to be formed?
Has Akeso Inc issued a profit warning in the past 24 months?
Does Akeso Inc disclose parental leave metrics?
Does Akeso Inc disclose climate scenario or pathway analysis?
Does Akeso Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Akeso Inc disclose the pay ratio of women to men?
Does Akeso Inc support suppliers with sustainability related research and development?
Does Akeso Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Akeso Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Akeso Inc involved in embryonic stem cell research?
Does Akeso Inc disclose GHG and Air Emissions intensity?
Does Akeso Inc disclose its waste policy?
Does Akeso Inc report according to TCFD requirements?
Does Akeso Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Akeso Inc disclose energy use targets?
Does Akeso Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Akeso Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Akeso Inc
These potential risks are based on the size, segment and geographies of the company.
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.